Cite
HARVARD Citation
Cyr, M. et al. (2022). Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia. Journal for immunotherapy of cancer. 10 (11), p. . [Online].